Previous studies reported that ponatinib can reduce inflammation of obesity and influenza (Chen et al., 2019; Lin et al., 2022) due to its inhibitory effect on the two isoforms of JAK (JAK1 and JAK2). The gene discussed is JAK2; the disease is obesity disorder.